🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Chemours expands board with new director appointment

EditorBrando Bricchi
Published 06/13/2024, 05:44 PM
CC
-

WILMINGTON, Del. - The Chemours Company (NYSE:CC), known for its market presence in industries such as Titanium Technologies and Thermal & Specialized Solutions, announced on Wednesday the addition of Livingston "Tony" Satterthwaite to its Board of Directors. The appointment, effective as of Monday, introduces Satterthwaite's extensive leadership experience to the Chemours governance team.

Satterthwaite, who is set to retire from his current role as Senior Vice President at Cummins, Inc. (NYSE:NYSE:CMI) in September 2024, has held various leadership positions during his 36-year career at the global power leader. His experience spans across multiple business units, including President of Power Generation and President of the Distribution Business.

Chair of the Chemours Board, Dawn Farrell, expressed confidence in Satterthwaite's proven track record in driving business growth, which she believes will complement the existing board's expertise. Denise Dignam, President and CEO of Chemours, also emphasized Satterthwaite's wealth of knowledge and is looking forward to the insights he will contribute to the board.

In addition to his role at Cummins, Satterthwaite serves on the Board of Directors for IDEX Corporation (NYSE:NYSE:IEX), the National Association of Manufacturers, and the Cummins Foundation. He is also an Industrial Advisory Council Member for Amprius, Inc. His academic credentials include an MBA from Stanford University and an undergraduate degree in civil engineering from Cornell University.

Chemours, headquartered in Wilmington, Delaware, serves a diverse range of industries with its portfolio of products, including well-known brands like Ti-Pure™, Opteon™, and Teflon™. The company operates 28 manufacturing sites, employs approximately 6,200 people, and caters to around 2,700 customers in roughly 110 countries.

The information in this article is based on a press release statement from The Chemours Company.

In other recent news, The Chemours Company has announced Shane Hostetter as its new Chief Financial Officer, effective from July 1, 2024. Hostetter, who brings over two decades of financial experience in the chemicals industry, notably served as CFO at Quaker Chemical (NYSE:KWR) Corporation since April 2021. He will now oversee Finance, Investor Relations, Corporate Development, Strategy, and Enterprise Risk Management at Chemours.

On the financial front, the company's first-quarter 2024 financial results showed a decrease in net sales by 6% to approximately $1.4 billion, and consolidated adjusted EBITDA fell by 37% to $193 million. However, the Titanium Technologies segment met top-line expectations, and adjusted EBITDA surpassed forecasts due to strategic volume allocations and cost reductions.

Analysts from Barclays, BMO Capital Markets, and UBS have provided price targets for Chemours, with projections ranging from $21.00 to $34.00. These projections are based on the company's recent developments, including the anticipated recovery in TiO2 volumes, strategic cost reductions, and a focus on its Advanced Performance Materials and Thermal & Specialized Solutions businesses. These are recent developments that investors should consider when evaluating the company's prospects.

InvestingPro Insights

The Chemours Company (NYSE:CC), while strengthening its board with industry expertise, also presents an interesting profile for investors examining its financial metrics. With a market capitalization of $3.8 billion, the company's valuation and stock performance seem to reflect its strategic moves and market challenges. Notably, Chemours is trading at a high Price / Book multiple of 5.06, which suggests that the market recognizes the value of the company's assets and its potential for future growth.

Recent trends in the company's performance have shown a decline in revenue growth, with the last twelve months as of Q1 2024 witnessing a decrease of 11.04%. This contraction is also reflected in the quarterly revenue growth for Q1 2024, which stands at -12.11%. Such figures highlight the current headwinds faced by the company, yet an "InvestingPro Tip" suggests that net income is expected to grow this year, indicating potential for a financial turnaround.

Despite the recent volatility in stock price movements, as pointed out by another "InvestingPro Tip," analysts predict the company will be profitable this year. This may provide some reassurance to investors concerned about the company's past performance, where it was not profitable over the last twelve months. For investors looking to delve deeper into the financial prospects of Chemours, there are additional "InvestingPro Tips" available, which can be accessed by visiting https://www.investing.com/pro/CC. Moreover, by using the coupon code PRONEWS24, readers can enjoy an extra 10% off a yearly or biyearly Pro and Pro+ subscription.

As Chemours continues to navigate the complexities of its industry sectors, these insights and additional tips from InvestingPro could prove invaluable for stakeholders making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.